Ann Marie O'Neill/aum.edu
May 20, 2026, 08:03
Ann Marie O’Neill: Help Us Improve Information for DOAC Medicines
Ann Marie O’Neill, Operations Manager at The Meath Foundation , Thrombosis Patient Advocate, shared a post on LinkedIn:
“We are inviting people who take Direct Oral Anticoagulant Medication (DOAC) eg. Apixaban (Eliquis) Rivaroxaban (Xaralto) or Dabigatran (Pradaxa) after experiencing a blood clot, to join a small focus group to help us improve our Patient information booklet.
If you are a VTE Health Care Professional, please share with your relevant Patients.
The more the merrier.”
Stay updated with Hemostasis Today.
-
Oct 15, 2026, 19:41Looking Beyond Platelet Counts to Quality of Life in ITP – American Society of Hematology
-
Oct 15, 2026, 19:32Markus Gregorio Barbosa: Hepatic VPS35 and Cholesterol Homeostasis
-
Oct 15, 2026, 19:18Emerging Novel Therapies for Hereditary Hemorrhagic Telangiectasia – The Lancet Haematology
-
Oct 15, 2026, 19:04Umberto Pensato: EVT Treatment Effects Across Perfusion Profiles in MeVO Stroke
-
Oct 15, 2026, 18:26Chanakya Nayudu: Presenting My Research at ISTH Congress 2026 in Paris
-
Oct 15, 2026, 18:09Maha Othman: Students Lead World Thrombosis Day 2026 Awareness Events
-
Oct 15, 2026, 17:52Jill de Mol։ Rapamycin Modulates Immune Responses in Aged Atherosclerosis
-
Oct 15, 2026, 17:41Victor Aboyans։ Think About Lipids in VTE
-
Oct 15, 2026, 17:08Babu Mia։ Targeting PPM1D to Eliminate Malignant Stem Cells in Myeloproliferative Neoplasms